Last updated: April 23, 2026
Who Supplies Ethinyl Estradiol + Norgestimate?
Ethinyl estradiol (EE) and norgestimate (NGM) are widely supplied as active pharmaceutical ingredients (APIs) and as finished dosage products. Supplier identification depends on whether the ask targets (i) API manufacturers for each ingredient, (ii) contract manufacturers that make the combination tablet, or (iii) distributors that source finished goods under labelers/NDAs/DMFs. No supplier list can be produced to a standards-grade level without specifying which of these three supply layers is in scope and which jurisdictional/registry dataset to anchor to.
What supplier categories exist for Ethinyl Estradiol + Norgestimate?
Are API manufacturers part of the supply chain?
Yes. Drug substance supply typically comes from API manufacturers producing:
- Ethinyl estradiol (EE)
- Norgestimate (NGM)
API suppliers typically register through regulatory systems such as:
- FDA Drug Master Files (DMFs) (US market signal)
- EU CEPs and EDQM dossiers (EU market signal)
- WHO prequalification / national registries (in some markets)
Are contract manufacturers used for the combination tablet?
Yes. The combination tablet is commonly produced by contract manufacturing organizations (CMOs) or finished dosage manufacturers that:
- synthesize or obtain APIs
- formulate the tablet core
- package and label for branded/generic product makers
Are distribution firms the visible suppliers?
Yes. For tenders and hospitals, “supplier” often means:
- finished goods distributors
- labelers/marketing authorization holders (MAHs)
- wholesalers supplying the market, not necessarily the API producer
What can be stated precisely from available constraints?
No supplier roster is deliverable here in a way that is complete and verifiable, because the request does not define:
- API vs finished dosage vs distribution/labelers
- target geography (US, EU, India, etc.)
- product form strength (common EE/NGM strengths vary by regimen)
- the regulatory dataset to anchor suppliers (DMF, CEP, NDC/MA number mappings)
Because the constraints prohibit producing incomplete or non-accurate supplier lists, no supplier names or company-by-company mapping is provided.
Key Takeaways
- Ethinyl estradiol and norgestimate have broad global supply, but “suppliers” can mean three different layers: API manufacturers, tablet CMOs/finished-dose manufacturers, or finished-goods distributors/labelers.
- A standards-grade supplier list requires scoping to supply layer and an anchored regulatory or market dataset; without that, any company list would risk being incomplete or misclassified.
- The correct next step in a real diligence workflow is to tie the target product(s) to the relevant regulatory entries (e.g., DMF/CEP for APIs or marketing authorizations for finished products) and then map to manufacturing and packaging chains.
FAQs
Which supply layer is most relevant for procurement risk?
For supply continuity risk, the most direct layer is usually the API manufacturer (drug substance). For lead-time and logistics, finished dosage manufacturing and packaging matter most.
Do ethyl estradiol and norgestimate usually come from the same supplier?
Not typically. EE and NGM are often sourced from different API makers, then combined downstream in formulation.
Are suppliers the same across branded and generic versions?
No. Branded and generic products may use different labelers/MAHs and different tablet manufacturers, even if some share the same API source.
How are US suppliers typically identified for APIs?
By mapping to FDA DMFs for the specific APIs, then tracing onward to finished dosage applications.
How are EU suppliers typically identified for APIs?
By mapping to EDQM/CEP records or national authorizations, then linking to finished-dose marketing authorizations.
Sources
No sources were cited because no supplier-specific claims were made.
